Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gorjan Hrustanovic

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Biology & Therapy|January 30, 2013
Mechanisms of resistance to EGFR targeted therapiesGorjan Hrustanovic, Bianca J Lee, Trever G Bivona
Human Molecular Genetics|June 28, 2013
Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndromeGhiabe-Henri Guibinga, Fiona Murray, Nikki Barron, et al.
Human Molecular Genetics|November 2, 2011
MicroRNA-mediated dysregulation of neural developmental genes in HPRT deficiency: clues for Lesch-Nyhan disease?Ghiabe-Henri Guibinga, Gorjan Hrustanovic, Kathryn Bouic, et al.
Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.
Cell Reports|April 7, 2015
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.
Nature Medicine|August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancerGorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.
Cell Reports|August 29, 2019
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and CancersNilanjana Chatterjee, Evangelos Pazarentzos, Manasi K Mayekar, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Molecular & Cellular Oncology|June 17, 2016
RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancerGorjan Hrustanovic, Trever G Bivona
Small Gtpases|February 23, 2016
RAS signaling in ALK fusion lung cancerGorjan Hrustanovic, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|December 15, 2015
RAS-MAPK in ALK targeted therapy resistanceGorjan Hrustanovic, Trever G Bivona
Cancer Biology & Therapy|January 30, 2013
Mechanisms of resistance to EGFR targeted therapiesGorjan Hrustanovic, Bianca J Lee, Trever G Bivona
Human Molecular Genetics|June 28, 2013
Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndromeGhiabe-Henri Guibinga, Fiona Murray, Nikki Barron, et al.
Human Molecular Genetics|November 2, 2011
MicroRNA-mediated dysregulation of neural developmental genes in HPRT deficiency: clues for Lesch-Nyhan disease?Ghiabe-Henri Guibinga, Gorjan Hrustanovic, Kathryn Bouic, et al.
Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.
Cell Reports|April 7, 2015
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.
Nature Medicine|August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancerGorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.
Cell Reports|August 29, 2019
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and CancersNilanjana Chatterjee, Evangelos Pazarentzos, Manasi K Mayekar, et al.
Pageof 1